CombiGene’s CEO Jan Nilsson guests AstraZeneca Exchange
The AstraZeneca Exchange networking events are held at AstraZeneca’s strategic R&D hubs in Gothenburg, Sweden and Cambridge, UK. The events are designed to provide opportunities for representatives from across the life science community to share knowledge and ideas. CombiGene’s CEO Jan Nilsson was invited on May 14th, together with Professor Johan Hyllner, Head of Regeneration, Early CVRM, R&D BioPharmaceuticals AstraZeneca (former Chief Scientific Officer at British CGT Catapult) and Professor Helena Brisby, Chief Physician, University of Gothenburg & Sahlgrenska University Hospital, to give a presentation under the heading Delivering advanced medicines to patients.
“To be invited to represent CombiGene at AstraZeneca Exchange is a very valuable expeprience,” says Jan Nilsson. “First of all, it is acknowledgement of the fact that CombiGene’s activities are gaining recognition in the industry, which is extremely gratifying. Secondly, it gives us fantastic opportunities to network with knowledgeable people. The event in Gothenburg gave me several new and valuable contacts and also exemplified how interest in gene therapy continues to grow.”
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.